Literature DB >> 19439242

Pregabalin augmentation to antidepressants in patients with major depressive disorder.

Chi-Un Pae.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19439242     DOI： 10.1016/j.pnpbp.2009.02.001

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN： 0278-5846            Impact factor:   5.067


× No keyword cloud information.
  6 in total

1.  Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.

Authors:  Ana Mańas; Juan Pablo Ciria; María Carmen Fernández; María Luisa Gonzálvez; Virginia Morillo; María Pérez; Xavier Masramon; Vanessa López-Gómez
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

Review 2.  Pregabalin in the treatment of alcohol and benzodiazepines dependence.

Authors:  Panagiotis Oulis; George Konstantakopoulos
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

3.  Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice.

Authors:  Kinga K Borowicz; Kamila Furmanek-Karwowska; Marta Morawska; Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Psychopharmacology (Berl)       Date:  2009-10-20       Impact factor: 4.530

Review 4.  NF-κB mediated regulation of adult hippocampal neurogenesis: relevance to mood disorders and antidepressant activity.

Authors:  Valeria Bortolotto; Bruna Cuccurazzu; Pier Luigi Canonico; Mariagrazia Grilli
Journal:  Biomed Res Int       Date:  2014-02-12       Impact factor: 3.411

5.  Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.

Authors:  Mariagrazia Grilli
Journal:  J Pain Res       Date:  2017-09-21       Impact factor: 3.133

6.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.